# Anna K. Nowak

Source: https://onco.cc/people/anna-nowak/  
OnCo record `anna-nowak` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma.

## Summary

Anna Nowak (University of Western Australia) led the DREAM phase 2 trial, the first to show durvalumab can be combined with first-line platinum-pemetrexed in mesothelioma, and is co-principal investigator of the international DREAM3R phase 3 trial with PrE0506. Her laboratory work on chemotherapy-induced immune modulation underpins the chemo-immunotherapy approach in the disease.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: mesothelioma; immunotherapy; australia
- Role: Professor of Medical Oncology and Dean of Medicine, University of Western Australia
- Specialisms: Mesothelioma; Immunotherapy; Chemo-immunotherapy combinations; Tumour immunology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Nowak%20AK%5BAuthor%5D%20mesothelioma%20durvalumab

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- institutions: [University of Western Australia](https://onco.cc/institutions/university-of-western-australia/)
- trials: [DREAM3R](https://onco.cc/trials/dream3r/)
- journals: [Clinical lung cancer](https://onco.cc/journals/clinical-lung-cancer/)

---
JSON: https://onco.cc/api/v1/entities/anna-nowak.json